Contracts & Grants was Celldex Therapeutics’s largest product and service line in fiscal 2025, bringing in $1.45M of $1.55M (94%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Contracts & Grants | $2.30M | $6.61M | $7.01M | $1.45M | |||||||
| Product Development & Licensing Agreements | $56.00K | $278.00K | $13.00K | $97.00K | |||||||
| Total | $2.36M | $6.88M | $7.02M | $1.55M |
Celldex Therapeutics brought in $1.55M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 78.0% from $7.02M in fiscal 2024. Contracts & Grants was the largest at $1.45M (93.7%), ahead of Product Development & Licensing Agreements at $97.00K (6.3%).
Compared with fiscal 2024, Product Development & Licensing Agreements grew 646.2% to $97.00K, while Contracts & Grants fell 79.3% to $1.45M. From fiscal 2022 to 2025, combined revenue from these lines fell from $2.36M to $1.55M, a compound annual decline of 13.1%. Contracts & Grants' share of the total fell from 97.6% to 93.7%.
Celldex Therapeutics (CLDX) reports its revenue by product and service. In fiscal 2025, Contracts & Grants was its largest product and service line, bringing in $1.45M (93.7% of the total), followed by Product Development & Licensing Agreements at $97.00K (6.3%).
Contracts & Grants was Celldex Therapeutics' largest product and service line in fiscal 2025, bringing in $1.45M, or 93.7% of the $1.55M total across its two product and service lines.
Product Development & Licensing Agreements grew faster than Contracts & Grants in fiscal 2025, up 646.2% from $13.00K to $97.00K. Contracts & Grants fell 79.3% to $1.45M.
Every figure comes from Celldex Therapeutics' annual financial filings, as reported. Each line keeps the name Celldex Therapeutics gives it, and years follow its fiscal calendar.
Celldex Therapeutics' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.